GlassScriptPhysician profile
Walter D Toronjo
NPI 1992720387
$2,198.92
in general payments reported to CMS, 2019-2025
26 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $84.85 · 2021: $369 · 2022: $816 · 2023: $195 · 2024: $301 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $394.67 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $377.45 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $208.31 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $206.39 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $190.94 | 2020-2023 | Eliquis |
| Cardiovascular Systems INC. | $175.38 | 2022 | |
| Lilly USA, LLC | $156.75 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Dexcom, INC. | $52.52 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $50.11 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $49.75 | 2021-2023 | Sapien 3 Ultra Resilia |
| Glaxosmithkline, LLC. | $48.68 | 2023-2024 | Shingrix, Arexvy |
| Genentech USA, INC. | $34.04 | 2019-2021 | |
| Boston Scientific Corporation | $23.97 | 2025 | Wavewriter Alpha Prime 16 |
| Sumitomo Pharma America, INC. | $21.83 | 2025 | Gemtesa |
| Abbvie INC. | $21.28 | 2023 | Ubrelvy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.13 | 2020 | |
| Astellas Pharma US INC | $20.42 | 2023 | Veozah |
| Paratek Pharmaceuticals, INC. | $19.72 | 2024 | Nuzyra |
| Abbott Laboratories | $17.10 | 2022 | |
| Hikma Pharmaceuticals USA | $16.72 | 2019 | |
| Clarus Therapeutics INC. | $16.30 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.15 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.02 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.84 | 2021 | |
| Amarin Pharma, INC. | $15.61 | 2019 | |
| Novo Nordisk INC | $11.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Toronjo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.